4.5 Article

Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5

Journal

BIOCHEMICAL JOURNAL
Volume 449, Issue -, Pages 151-159

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/BJ20121280

Keywords

histone methyltransferase; leukaemia; mixed-lineage leukemia protein (MLL); WD40 repeat protein 5 (WDR5)

Funding

  1. Canadian Institutes of Health Research
  2. Eli Lilly Canada
  3. Genome Canada
  4. GlaxoSmithKline
  5. Ontario Ministry of Economic Development and Innovation
  6. Novartis Research Foundation
  7. Pfizer
  8. AbbVie
  9. Takeda
  10. Wellcome Trust

Ask authors/readers for more resources

WDR5 (WD40 repeat protein 5) is an essential component of the human trithorax-like family of SET1 [Su(var)3-9 enhancer-of-zeste trithorax 1] methyltransferase complexes that carry out trimethylation of histone 3 Lys(+) (H3K4me3), play key roles in development and are abnormally expressed in many cancers. In the present study, we show that the interaction between WDR5 and peptides from the catalytic domain of MLL (mixed-lineage leukaemia protein) (KMT2) can be antagonized with a small molecule. Structural and biophysical analysis show that this antagonist binds in the WDR5 peptide-binding pocket with a K-d of 450 nM and inhibits the catalytic activity of the MLL core complex in vitro. The degree of inhibition was enhanced at lower protein concentrations consistent with a role for WDR5 in directly stabilizing the MLL multiprotein complex. Our data demonstrate inhibition of an important protein-protein interaction and form the basis for further development of inhibitors of WDR5-dependent enzymes implicated in MLL-rearranged leukaemias or other cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available